TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Accuracy of the nomogram for predicting MIS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: VR cybersickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of ventilator-associated pneumonia (VAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: QUICK DASH score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Unplanned intensive care unit admission
Endpoint domain: Adverse events/effects
Primary endpoint: mean increase in lateral opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of feces expelled
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Lifetime prevalence of allergic diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Risk of atopic dermatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequency of renal colic episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Need for antalgic
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: external training load (TL) metrics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: session rating of perceived exertion (sRPE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to the first exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total HADS score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Residual displacement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ozone-induced airway inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: clearance in the large airways
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Financial assistance application and receipt
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Patient‐Rated Wrist and Hand Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CVS-Q© scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ≥75% thrombus removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: symptomatic pulmonary embolus
Endpoint domain: Adverse events/effects
Primary endpoint: Adherence to antibiotic treatment guidelines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-spinal anesthesia hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in control and inhibition of reactions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improvements in abstract thinking
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Improvements in categorization
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Skin lightening efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: 5-year LRR-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Caregivers' understanding of discharge information
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Motor scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Positive Modified-Checklist for Autism in Toddlers screening
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Physical signs scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aesthetic evaluation of breast appearance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Overall mortality at 1-year
Endpoint domain: Mortality/survival
Primary endpoint: emotional dimension of quality of life
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: social dimension of quality of life
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: school dimension of quality of life
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Severity of coughing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SpO2 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: postoperative pain during activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative pain during coughing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative levels of C-reactive protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TEAM leadership
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TEAM task management
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment difference for TMV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: less medication usage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: less extensive anterior synechiae
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lower incidence of blindness
Endpoint domain: Adverse events/effects
Primary endpoint: dead-space ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: URTI symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: persistent worsening renal function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Proportion of children who continued vomiting within the first 4 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Craving and use of cannabis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery of swallowing ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Predicting metastatic LN status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Predicting LN metastasis degree
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: AUC of the radiomic nomogram
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptomatic Stress Urinary Incontinence (SUI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: SARS-CoV-2 undetectability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: E. coli cultures at 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Filtration efficiency and breathing resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: composite of a sustained decline in eGFR of ≥50%, end‐stage renal disease, renal death or cardiovascular death
Endpoint domain: Mortality/survival
Primary endpoint: AASIS scores improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: SALT scores improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: QoR-40 recovery scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: NLR values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mental distress improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Emotional distress improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Digital screen exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of home discharges
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short-term revision rate
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative 24-h morphine consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual analog scale scores at rest and at abduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of mosquitoes infected by Plasmodium falciparum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Plasma triacylglycerol 8‐h incremental area under the curves
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: VLDL particle concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Febrile neutropenia rates
Endpoint domain: Adverse events/effects
Primary endpoint: Immunosuppressive profile (NLR >5 at day 8)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cognition improvement measured by ADAS-Cog12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose interruption, reduction and discontinuation rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Average cost of PARPi therapy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Non-inferiority of darbepoetin alpha to rHuEPO for treatment of anemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety profile comparison between darbepoetin alpha and rHuEPO
Endpoint domain: Adverse events/effects
Primary endpoint: Cost reduction per patient by shifting to darbepoetin alpha
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of postoperative complications at the donor site
Endpoint domain: Adverse events/effects
Primary endpoint: VSS score of scar at the donor site
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Scar width at the donor site
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: z-BMI change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: z-weight change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: z-height change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in ARV from pre- to post-intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean systolic BP during the intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean diastolic BP during the intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in Urgency Urinary Incontinence (UUI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stress levels of infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vital signs of infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients achieving IOP ≤ 16 mmHg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients achieving at least a 40% reduction from baseline in mean diurnal IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Epoetin dosage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ND: YAG capsulotomy rate
Endpoint domain: Adverse events/effects
Primary endpoint: sEMG values of quadriceps femoris
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: strength of quadriceps femoris
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Therapy related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: C5 protein reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sensitivity to detect vCDR>0.5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity to detect vCDR>0.5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of intervention participants accepting referrals
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: COVID-19-associated hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Difficulty in using eye drops
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: excellent functional outcome
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Pain perception during rubber dam placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade ≥ 3 treatment-emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Vocal self-perception
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Voice-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: SAMS (Statin-Associated Muscle Symptoms)
Endpoint domain: Adverse events/effects
Primary endpoint: Statin discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Actinobacteria abundance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abundance of Bacillus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PIVC failure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6MWT (6-Minute Walk Test) improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: definitive diagnoses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: diagnoses of acute lung rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: diagnoses of rejection severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rescue midazolam requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean RSS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptance and uptake of digital devices
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: risk of seizure recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Reduction of mean IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Change in outcome measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in OSAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elastin grading improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TGFβ1 levels improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Understanding of placebo control in surgery
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximum clot firmness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Coagulation indexes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Composite renal endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Days of hospitalization avoided
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Reduction in INV angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in CSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: respiratory arousal threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Improvement in HFMSE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery as measured by EQ-5D health index
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: mean blood-loss volume during the first 24 postoperative hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of SRI4 responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of severe SFI flare
Endpoint domain: Adverse events/effects
Primary endpoint: MMS score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: stone expulsion rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: α-diversity (Shannon index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lactococcus spp. abundance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum energy metabolites (pyruvate and lactate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bleeding control success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of bleeding (VAS score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of applications needed for bleeding control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Postoperative hip pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Cardiovascular disease risk associated with WMH volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 7-day ppa
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: ΔQ values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Costs per participant
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: VAS scores post injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bioequivalence of CF formulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concordance rate of HrHPV test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive rate of cytology (ASCUS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge scores at post-test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: organ/space SSI
Endpoint domain: Adverse events/effects
Primary endpoint: sepsis/septic shock
Endpoint domain: Adverse events/effects
Primary endpoint: Composite suicidality scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Intestinal maximum wall thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Enhancement (PE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Task completion time interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: System Usability Scale (SUS) value
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: ≥10-point improvement in KCCQ-OS
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: risk for death or HF hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Access to community rehabilitation and psychosocial interventions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: worsening depressive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: New-onset AF diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 7-day ischaemic outcome of death, myocardial infarction or stroke
Endpoint domain: Mortality/survival
Primary endpoint: Thrombolysis In Myocardial Infarction major and minor bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Number of new clients using injectables
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-injection uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change from baseline of tCFS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Upper inter-canine distance increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Upper inter-molar width increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maxillary total arch perimeter increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: severe RIL
Endpoint domain: Adverse events/effects
Primary endpoint: end-of-life trajectory intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rotator cuff dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Limited AROM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Scapular dyskinesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: ASES score improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: WORC score improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of cosmetic deformity
Endpoint domain: Adverse events/effects
Primary endpoint: neurologic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Hospitalization for any cause
Endpoint domain: Mortality/survival
Primary endpoint: Postdischarge mortality risk
Endpoint domain: Mortality/survival